Illumina MiSeq i100 Series system

Solicitation / RFP / RFQ

This solicitation is an RFQ for the purchase of one (1) Illumina MiSeq i100 Plus Sequencing System. It is issued by the Department of the Interior (DOI)/Interior Business Center (IBC) on behalf of the U.S. Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Cancer Institute (NCI), Center for Cancer Research (CCR).

• Procurement of one (1) Illumina MiSeq i100 Plus Sequencing System.

• The system must be brand-name only; no substitutions or equivalent products are allowed.

• Offerors must be either the manufacturer (Illumina) or an authorized reseller, and must provide documentation verifying reseller status.

• Offerors must confirm the capability to provide all required training and meet the delivery timeline.

• Delivery and installation are required within four to twelve weeks after contract award.

• Training on the use of the equipment, software, and workflows must be provided within one week of installation.

• Contract Type: Firm-Fixed-Price (FFP) Purchase Order.

• Period of Performance/Delivery: Within four to twelve weeks after contract award.

• Estimated Value: Not specified, but offerors are encouraged to propose discounts.

• Questions Due: May 18, 2026, 10:00 AM Eastern Time.

• Quotes Due: May 20, 2026, 10:00 AM Eastern Time.

• Submission Method: Electronically via email to Bridgette Ornelas at bridgette_ornelas@ibc.doi.gov.

• Evaluation Criteria: Lowest-priced technically acceptable (LPTA).

• Technical acceptability will be based on:

  1. Brand-Name Confirmation (Illumina MiSeq i100 Plus System, correct item/catalog number).
  2. Authorized Source Statement (manufacturer or authorized reseller).
  3. Training and Delivery Capability.

• Quotes must remain valid for 30 days after submission.

• This is a notice of limited sources due to a brand-name requirement.

• Only Illumina and authorized Illumina dealers are eligible to submit quotes.

• This acquisition is not set aside for small business concerns.

• NAICS Code: 334516 Analytical Laboratory Instrument Manufacturing.

• Product Service Code: 6650 – Optical Instruments, Test Equipment, Components and Accessories.

• Attachment 1: Statement of Need.

• Invoicing will be processed through the Invoice Processing Platform (IPP).

Statement of Need (SON)

To replace existing Illumina iSeq and legacy MiSeq instruments with a single Illumina MiSeq i100 Series system to ensure reliable and sustainable sequencing services for the Center for Cancer Research Genomics Core. This consolidation aims to reduce service contracts, consumables, operational complexity, and risk of service interruptions, while providing investigators with access to a current, fully supported platform.

• Procurement of one Illumina MiSeq i100 Series system.

• Delivery and installation of the system within four to twelve weeks after contract award at the CCR Genomics Core.

• Provision of training on the equipment, software, and associated workflows for National Cancer Institute researchers within one week of installation.

• The system must be capable of delivering up to 100 million reads (30 gigabases) per run.

• Run times should be approximately four hours to enable same-day results.

• Delivery and installation: Within four to twelve weeks after contract award.

• Location: CCR Genomics Core, Bethesda, MD.

• Sequencing chemistries must be compatible with other Illumina sequencing systems, including government-owned platforms.

• Must utilize XLEAP-SBS chemistry for improved data accuracy, faster run times, and increased reliability.

• Must include an integrated onboard DRAGEN platform for secondary data analysis.

• Must provide application support for targeted sequencing panels and whole-genome sequencing.

• Training to be conducted by a premium support scientist or other qualified Illumina personnel.

• Additional training available on an as-needed basis.

Firm Fixed-Price Purchase Order.

Notice of Intent to Sole Source

This document announces the U.S. Department of the Interior's intent to negotiate a sole source, firm-fixed-price acquisition with Illumina, Inc. for one (1) Illumina MiSeq i100 Plus Sequencing System. This system is intended for the U.S. Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Cancer Institute (NCI), Center for Cancer Research (CCR).

The CCR requires this system to replace aging iSeq and legacy MiSeq instruments and to support centralized sequencing operations. The MiSeq i100 Plus is expected to provide improved run reliability, streamlined workflows, and flexible support for small- and mid-scale sequencing projects. Illumina is identified as the sole Original Equipment Manufacturer (OEM) with the capability to provide this specific system, its associated consumables, integrated secondary analysis functionality, and required installation and training services. Procuring from the OEM ensures compatibility with existing government-owned Illumina platforms and avoids operational interruptions.

CCR Genomics Core, National Cancer Institute, 37 Convent Drive, MSC 4256, Bethesda, MD 20892-4256.

While this action is being processed as a sole source, other entities are invited to express their interest and demonstrate their capability by submitting a capability statement. The submission deadline is 10:00 A.M. ET, Monday, April 20, 2026. Submissions must not exceed ten (10) pages and should be in a Microsoft Office compatible format or Adobe Acrobat. The maximum file size is 8 MB. Late responses will only be accepted if they contain extraordinary value. Marketing brochures and generic company literature will not be considered. The Government reserves the right to issue a Request for Quote (RFQ) based on responses received.

Delivery is required no later than 12 weeks after contract award.

Notice of Intent to Sole Source

This notice announces the U.S. Department of the Interior's intent to negotiate a sole source, firm-fixed-price acquisition with Illumina, Inc. The acquisition is for one (1) Illumina MiSeq i100 Plus Sequencing System, including delivery, installation, and training. This system is intended for the U.S. Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Cancer Institute (NCI), Center for Cancer Research (CCR).

• One (1) Illumina MiSeq i100 Plus Sequencing System.

• The system is required to replace aging iSeq and legacy MiSeq instruments.

• It will support centralized sequencing operations, improve run reliability, streamline workflows, and provide flexible support for small- and mid-scale sequencing projects.

• The OEM (Illumina) is stated as the only entity with the authorized capability to provide this system, associated consumables compatibility, integrated DRAGEN secondary analysis functionality, and required installation and training services.

• Procuring from the OEM ensures compatibility with existing Government-owned Illumina platforms and avoids interruptions.

• Contract Type: Firm-Fixed-Price (FFP)

• Delivery: No later than 12 weeks after contract award.

• This is a Notice of Intent to Sole Source, not a request for competitive quotes.

• Interested parties may express their interest and demonstrate capability by submitting a capability statement.

• Capability statements are due by 10:00 A.M. ET, Monday, April 13, 2026.

• Submissions should be sent electronically to Bridgette Ornelas (bridgette_ornelas@ibc.doi.gov) and Desmond Harris (desmond_harris@ibc.doi.gov).

• Submissions shall not exceed ten (10) pages and must be in a Microsoft Office compatible format or Adobe Acrobat.

• The maximum file size for submissions is 8 MB.

• The Government will consider capability statements received by the deadline.

• A determination not to compete this action based on responses is solely within the Government's discretion.

• Information received is for determining whether to conduct a competitive acquisition.

• The Government reserves the right to issue an RFQ.

• This is currently intended as a sole source acquisition.

• The Government will not reimburse for any information or administrative costs incurred in response to this notice.

• Marketing brochures and generic company literature will not be considered.

• Not addressing all requested information may result in the Government determining the responder is not capable of performing the scope of work.